Last reviewed · How we verify
NCT03501134: ACTION
Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields
trial testing NovoTTF in Malignant Glioma in 20 participants. Completed in 3 June 2021.
3 June 2021
Quick facts
| Lead sponsor | Duke University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 8 August 2018 |
| Primary completion | 3 June 2021 |
| Estimated completion | 3 June 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- NovoTTF
Conditions studied
- Malignant Glioma — all drugs for Malignant Glioma →
Sponsor
Duke University
Who can join
18 and older, any sex, with Malignant Glioma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This purpose of this study is to describe the effect of Tumor Treating Fields (NovoTTF) on quality of life (QOL), including exercise, sleep quality, and mood, in patients with World Health Organization (WHO) Grade IV malignant glioma who have been prescribed and approved to receive Optune™. This is an observational, longitudinal study, meaning that information about QOL will be collected over time while the patient is using the NovoTTF device (for example, Optune™).
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Tumor-Treating Fields in Glioblastomas: Past, Present, and Future.
Guo X, Yang X, Wu J, Yang H, et al · · 2022 · cited 39× · PMID 35954334 · DOI 10.3390/cancers14153669 -
Advancements and current trends in tumor treating fields: a scientometric analysis.
Xing Y, Yasinjan F, Cui J, Peng Y, et al · · 2024 · cited 9× · PMID 38349201 · DOI 10.1097/js9.0000000000001151 -
A Holistic Approach to Hard-to-Treat Cancers: The Future of Immunotherapy for Glioblastoma, Triple Negative Breast Cancer, and Advanced Prostate Cancer.
Puig-Saenz C, Pearson JRD, Thomas JE, McArdle SEB. · · 2023 · cited 4× · PMID 37626597 · DOI 10.3390/biomedicines11082100
Verify or expand the search:
- PubMed search for NCT03501134
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Malignant Glioma
Currently open trials in the same condition.
- NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
- NCT07447531 — T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas · NA · recruiting
- NCT06470711 — Mapping of Electrical Properties in the Brain · recruiting
- NCT05717153 — Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma · EARLY_PHASE1 · recruiting
- NCT05030298 — Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial · Phase 1 · recruiting
Other Duke University trials
Trials by the same sponsor.
- NCT07216456 — Vaginal Dilator Therapy After Pelvic Radiation · NA · not yet recruiting
- NCT07519317 — Dosing and Deployment Trial: A Home-based Optokinetic Treatment · NA · not yet recruiting
- NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
- NCT07216963 — The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study · NA · not yet recruiting
- NCT07459218 — IDEAS for Hope to Reduce Suicide Risk and Improve HIV Care Engagement in Tanzania · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03501134 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Duke University
- Last refreshed: 9 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03501134.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing